AU2007226542B2 - Peptidomimetic inhibitors of PSMA,compounds comprising them, and methods of use - Google Patents

Peptidomimetic inhibitors of PSMA,compounds comprising them, and methods of use Download PDF

Info

Publication number
AU2007226542B2
AU2007226542B2 AU2007226542A AU2007226542A AU2007226542B2 AU 2007226542 B2 AU2007226542 B2 AU 2007226542B2 AU 2007226542 A AU2007226542 A AU 2007226542A AU 2007226542 A AU2007226542 A AU 2007226542A AU 2007226542 B2 AU2007226542 B2 AU 2007226542B2
Authority
AU
Australia
Prior art keywords
alkyl
compound
amino
hydroxy
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007226542A
Other languages
English (en)
Other versions
AU2007226542A1 (en
Inventor
Cliff Berkman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Targeted Technology LLC
Original Assignee
Cancer Targeted Technology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Targeted Technology LLC filed Critical Cancer Targeted Technology LLC
Publication of AU2007226542A1 publication Critical patent/AU2007226542A1/en
Application granted granted Critical
Publication of AU2007226542B2 publication Critical patent/AU2007226542B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/222—Amides of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2408—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2416—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2429—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of arylalkanols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Pyrane Compounds (AREA)
AU2007226542A 2006-03-14 2007-03-14 Peptidomimetic inhibitors of PSMA,compounds comprising them, and methods of use Active AU2007226542B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78221106P 2006-03-14 2006-03-14
US60/782,211 2006-03-14
PCT/US2007/064002 WO2007106869A1 (en) 2006-03-14 2007-03-14 Peptidomimetic inhibitors of psma,compounds comprising them, and methods of use

Publications (2)

Publication Number Publication Date
AU2007226542A1 AU2007226542A1 (en) 2007-09-20
AU2007226542B2 true AU2007226542B2 (en) 2013-08-22

Family

ID=38229662

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007226542A Active AU2007226542B2 (en) 2006-03-14 2007-03-14 Peptidomimetic inhibitors of PSMA,compounds comprising them, and methods of use

Country Status (9)

Country Link
US (3) US7696185B2 (https=)
EP (1) EP1999136B1 (https=)
JP (1) JP2009532338A (https=)
CN (1) CN101443340B (https=)
AU (1) AU2007226542B2 (https=)
CA (1) CA2645809C (https=)
ES (1) ES2397973T3 (https=)
PL (1) PL1999136T3 (https=)
WO (1) WO2007106869A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700234T3 (es) 2007-06-26 2019-02-14 Univ Johns Hopkins Inhibidores marcados del antígeno de membrana específico de la próstata (PSMA), evaluación biológica y uso como agentes para la obtención de imágenes
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
WO2010045598A2 (en) * 2008-10-17 2010-04-22 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
WO2010149666A1 (en) * 2009-06-22 2010-12-29 Medexis S.A. Methods for treating neoplasia
EP2338892A1 (en) 2009-12-18 2011-06-29 Bayer Schering Pharma Aktiengesellschaft Prostate specific membrane antigen inhibitors
CA2790577A1 (en) * 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
JP5657902B2 (ja) * 2010-03-17 2015-01-21 株式会社コスモステクニカルセンター ポリオキシアルキレンステロールエーテル誘導体及び／又はポリオキシアルキレンスタノールエーテル誘導体、及びそれを含有する外用剤組成物
US9328129B2 (en) * 2010-11-12 2016-05-03 Washington State University Peptidomimetic inhibitors of PSMA
WO2012174136A1 (en) * 2011-06-15 2012-12-20 Cancer Targeted Technology Llc Chelated psma inhibitors
WO2013173583A1 (en) 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Psma inhibitors
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
PL2970345T3 (pl) * 2013-03-15 2019-12-31 Cancer Targeted Technology Llc Znakowane 18F środki do obrazowania PET ukierunkowane na PSMA
EP2842578B1 (en) 2013-08-27 2018-06-27 GILUPI GmbH Diagnostic device for the detection of biomarkers
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3533473A3 (en) 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
US10383912B2 (en) * 2014-08-18 2019-08-20 Washington State University Tunable pH-sensitive linker for controlled drug release
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US9808538B2 (en) * 2015-09-09 2017-11-07 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
AU2017311510B2 (en) 2016-08-10 2021-11-18 Cancer Targeted Technology Llc Chelated PSMA inhibitors
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
IL287989B2 (en) * 2019-05-13 2025-07-01 Bracco Imaging Spa Modified cyanine dyes and their conjugates
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
WO2021046233A1 (en) 2019-09-03 2021-03-11 Cancer Targeted Technology Llc Chelate-containing psma inhibitors
CN113117100B (zh) * 2019-12-31 2024-03-01 广东精观生物医药科技有限公司 一种靶向psma的荧光分子探针及其制备方法和应用
CN111675747B (zh) * 2020-07-30 2021-04-27 中国医学科学院医药生物技术研究所 抗肿瘤药物和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110723A1 (en) * 2001-02-07 2004-06-10 Frangioni John V. Modified psma ligands and uses related thereto

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US782211A (en) 1904-05-23 1905-02-07 George W Sturgis Vending-wagon.
RU2218179C2 (ru) * 1996-06-17 2003-12-10 Гилфорд Фармасьютикалз Инк. СПОСОБЫ ЛЕЧЕНИЯ РАКА С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ NAALADазы
ATE362107T1 (de) * 2000-11-20 2007-06-15 Eastern Virginia Med School Verfahren und vorrichtungen zum quantitativen nachweis eines prostata-spezifischen membranantigens und anderer prostatamarker
CA2474616A1 (en) * 2002-01-28 2003-08-07 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (psma)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110723A1 (en) * 2001-02-07 2004-06-10 Frangioni John V. Modified psma ligands and uses related thereto

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEN, Y. et al, Phosphorus, Sulfur and Silicon, 1991, vol. 61, no. 1-2, pages 31-39 *
FATHY EL ETREBY, M. et al, The Prostate, 2000, vol. 43, no. 1, pages 31-42 *
LI, Y. et al, Bioorganic Chemistry, 1992, vol. 20, pages 285-295 *
MAUNG, J. et al, 229th National Meeting of the American Chemical Society, San Diego, USA, March 13-17, vol. 229, 13 March 2005, abstract 480 *
MAUNG, J. et al, Bioorganic and Medicinal Chemistry, 2004, vol. 12, no. 18, pages 4969-4979 *
TANG, H. et al, Biochemical and Biophysical Research Communications, 2003, vol. 307, no. 1, pages 8-14 *

Also Published As

Publication number Publication date
JP2009532338A (ja) 2009-09-10
US7696185B2 (en) 2010-04-13
US20070219165A1 (en) 2007-09-20
CN101443340A (zh) 2009-05-27
US8293725B2 (en) 2012-10-23
EP1999136B1 (en) 2012-10-24
USRE42275E1 (en) 2011-04-05
EP1999136A1 (en) 2008-12-10
PL1999136T3 (pl) 2013-03-29
WO2007106869A1 (en) 2007-09-20
CN101443340B (zh) 2013-12-04
CA2645809C (en) 2015-05-26
US20100183517A1 (en) 2010-07-22
CA2645809A1 (en) 2007-09-20
AU2007226542A1 (en) 2007-09-20
ES2397973T3 (es) 2013-03-12

Similar Documents

Publication Publication Date Title
AU2007226542B2 (en) Peptidomimetic inhibitors of PSMA,compounds comprising them, and methods of use
US5968915A (en) Naaladase inhibitors
HUP9902636A2 (hu) NAALADáz inhibtor hatású foszfinil-származékok és ezeket tartalmazó gyógyszerkészítmények
JP2006523237A (ja) Ｐｉ−３キナーゼインヒビタープロドラッグ
JP2006523237A5 (https=)
WO2017041720A1 (zh) 作为高效的疫苗佐剂的甲羟戊酸通路的抑制剂
EP3497095A1 (en) Compounds
ES2743276T3 (es) Derivados de ácido hidroxibisfosfónico bifuncionales
US8324378B2 (en) Prodrugs and conjugates of prenylation inhibitors
AU639495B2 (en) Gem-diphosphonic acids, a process for the preparation thereof and pharmaceutical compositions containing them
HUP0301711A2 (hu) Elágazó láncú lipofil molekulák származékai és alkalmazásuk
JPS63239291A (ja) 新規ヘテロ環置換ジホスホネート化合物、医薬組成物並びにカルシウム及びリン酸代謝異常の治療方法
KR101327635B1 (ko) 포스폰산화 리파마이신, 및 그의 뼈 및 관절 감염의 저지및 치료 용도
EP3307747A1 (en) Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof
JP6706799B2 (ja) 新規ビスホスホン酸誘導体及びその用途
US20060210479A1 (en) Targeting chelants and chelates
KR102497821B1 (ko) 신규 mTOR 억제제 화합물 및 이의 용도
WO2017053486A1 (en) Bone active nitrogen-containing bisphosphonates with a near infrared fluorescent label
BRPI0610022A2 (pt) compostos fluoroquinolonas fosfonadas, seus análogos antibacterianos, composição farmacêutica que os contém, bem como o uso dos mesmos
KR102486721B1 (ko) 신규 mTOR 억제제 화합물 및 이의 용도
WO2012174121A2 (en) Decoquinate prodrugs

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)